Paragon Health Institute Icon White

In Omnibus Bill, Health Lobbyists Win, We Lose

President at Paragon Health Institute
Brian Blase, Ph.D., is the President of Paragon Health Institute. Brian was Special Assistant to the President for Economic Policy at the White House’s National Economic Council (NEC) from 2017-2019, where he coordinated the development and execution of numerous health policies and advised the President, NEC director, and senior officials. After leaving the White House, Brian founded Blase Policy Strategies and serves as its CEO.
Senior Policy Analyst at Paragon Health Institute
Joe Albanese is a Senior Policy Analyst with Paragon Health Institute. He comes to Paragon with over six years of federal and nonprofit public policy experience.
Former Senior Policy Analyst
Drew Keyes is a former Senior Policy Analyst at the Paragon Health Institute. Drew brings nearly a decade of experience as a Congressional staffer, where he worked to advance conservative, free-market principles.

The omnibus is Washington at its worst. It’s a huge end-of-year $1.7 trillion spending bill loaded with significantly expanded government authorities and programs and little opportunity for most members of Congress, much less the American public, to review it. This bill also shows that neither Congress nor the White House is serious about huge annual budget deficits and 40-year-high inflation, choosing instead to double down on reckless fiscal policy. Of course, special interests are never fully happy, but this is a windfall for industries with lobbying power. While there were some members in Congress fighting to keep some of the worst provisions out, unfortunately, the bill expands government, subsidizes big business, and ignores the interests of taxpayers while circumventing regular order in Congress.

The Food and Drug Administration (FDA) has come under significant scrutiny following controversies relating to Covid-19infant formula, and slower drug approvals. Congress reauthorizes the agency every five years and usually takes the opportunity to reform its operations.

This year, however, reforms were not included in the FDA’s reauthorization process, removing the chance for substantive debate around reform. The omni is being used as a vehicle to stuff some of those priorities into a larger bill.

The full article can be found in National Review.

Related Content


Sign up now for your health policy updates.

This field is for validation purposes and should be left unchanged.